Toxoplasmosis during pregnancy can cause congenital malformations and fetal death. This study aimed to estimate the Toxoplasma gondii seroprevalence among pregnant women participating in the 2021 French national perinatal survey and identify associated factors. All women giving birth in France during the study period were invited to participate. Data collected included demographic information, nationality, socio-economic status, education level, and Toxoplasma gondii serological status. Women were classified as seropositive if IgG antibodies were present or if seroconversion occurred during pregnancy. Univariate and multivariate Poisson regression analyses with robust error variance were used to estimate prevalence ratios and identify factors associated with seropositivity. Among 12,612 women, the overall seroprevalence was 25.9%, and 0.22% seroconverted during pregnancy. Seroprevalence increased by 5% with every 5-year age increment and was significantly higher in the French overseas territories of Mayotte (75.0%), La Réunion (35.8%), and French Guiana (33.3%). Seroprevalence was also higher among women with lower educational levels (47.4% for primary education) and those of Sub-Saharan African nationality (52.0%). Geographic and socio-demographic variations may reflect dietary and environmental diversity. Despite declining seroprevalence in France, continued public health efforts, particularly among high-risk populations, remain critical to minimize the impact of congenital toxoplasmosis.

Toxoplasmosis, caused by the obligate intracellular parasite Toxoplasma gondii, is one of the most prevalent zoonotic parasitic infections worldwide. When acquired during pregnancy, T. gondii can be transmitted to the fetus, with clinical outcomes influenced by gestational age at time of infection and the parasite’s genotype. Prenatal screening enables the detection of maternal seroconversion and offers a critical window for intervention. In Uruguay, despite mandatory serological screening during pregnancy, national data on T. gondii seroprevalence and maternal seroconversion have not been updated in two decades. In addition, the genetic diversity of local strains remains poorly characterized. In this study, we analysed publicly available serological data from pregnant individuals attending Uruguay’s largest public maternity hospital between 2019 and 2023. We found that seroprevalence has modestly declined from 50% (reported in 1998) to 45.5%, with a congenital transmission rate of 0.58%. Clinical analysis of affected newborns revealed chorioretinitis as the predominant manifestation. To investigate parasite diversity, we performed genotyping of T. gondii strains using in silico PCR-RFLP following molecular detection. Our findings revealed substantial genetic diversity, including novel allele combinations not previously described in the region. These results highlight both the continued public health burden and the evolving genetic landscape of T. gondii in Uruguay. Our findings underscore the need to strengthen surveillance and prevention strategies for congenital toxoplasmosis in South America.

There is limited information on the antibody responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in subjects from developing countries with populations having a high incidence of co-morbidities. Here, we analysed the immunogenicity of homologous schemes using the ChAdOx1-S, Sputnik V, or BNT162b2 vaccines and the effect of a booster dose with ChAdOx1-S in middle-aged adults who were seropositive or seronegative to the SARS-CoV-2 spike protein before vaccination. The study was conducted post-vaccination with a follow-up of 4 months for antibody titre using enzyme-linked immunosorbent assay (ELISA) and pseudovirus (PV) neutralization assays (PNAs). All three vaccines elicited a superior IgG anti-receptor-binding domain (RBD) and neutralization response against the Alpha and Delta variants when administered to individuals with a previous infection by SARS-CoV-2. The booster dose spiked the neutralization activity among individuals with and without a prior SARS-CoV-2 infection. The ChAdOx1-S vaccine induced weaker antibody responses in infection-naive subjects. A follow-up of 4 months post-vaccination showed a drop in antibody titre, with about 20% of the infection-naive and 100% of SARS-CoV-2 pre-exposed participants with detectable neutralization capacity against Alpha pseudovirus (Alpha-PV) and Delta PV (Delta-PV). Our observations support the use of different vaccines in a country with high seroprevalence at the vaccination time.

The hepatitis E virus (HEV) has been described in humans and various animal species in different regions of the world. However, the knowledge on natural HEV infection in non-human primates and the corresponding risk of zoonotic transmission is scarce. To determine whether primates in captivity are affected by HEV infection, we investigated 259 individual sera of clinically healthy non-human primates of 14 species from nine German zoos. Using a commercial double-antigen-sandwich ELISA and a commercial IgG ELISA, 10 animals (3·9%) reacted positive in at least one assay. Three ape species and one Old World monkey species were among the seropositive animals: bonobo (Pan paniscus), gorilla (Gorilla gorilla gorilla), lar gibbon (Hylobates lar) and drill (Mandrillus leucophaeus). Testing for anti-HEV-IgM antibodies by commercial ELISA and for viral RNA by reverse-transcription real-time polymerase chain reaction resulted in negative results for all animals indicating the absence of acute HEV infections. In the past, no clinical signs of hepatitis were recorded for the seropositive animals. The results suggest that non-human primates in zoos can get naturally and subclinically infected with HEV or related hepeviruses. Future studies should evaluate potential sources and transmission routes of these infections and their impact on human health.

Passive immunity against measles decreases during the first months of life. The objective of this study was to determine titres of measles antibodies in children aged 9–14 months and their mothers before vaccination, and the children's response to vaccination. Blood samples were collected by capillary puncture before and 28 days after vaccination. Samples were obtained between February and June 2007 during an ongoing measles outbreak. Titres of specific measles IgG antibodies were determined by enzyme-linked immunosorbent assay. Seroconversion was defined as the presence of antibodies after vaccination in subjects without antibodies before vaccination. Maternal antibodies were present in 37·7% of all 69 children included and in 45·1% of children aged 9 months. Of the 51 children in whom a second sample was obtained, 31 (60·8%) were seronegative before vaccination and 61·3% seroconverted. Interference of maternal antibodies was 30%. Advancing the first dose of measles vaccination from 15 to 12 months is a correct strategy, given the increase in the time of susceptibility of infants to measles.